Efficacy and safety of lansoprazole in treatment of Zollinger-Ellison syndrome. First six months of follow-up;Efficacite et tolerance du lansoprazole dans le traitement du syndrome de zollinger-ellison. Etude sur les six premiers mois de traitement

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 10, 1998, Pages 801-808

  Pospaï, Dan ^a   Cadiot, Guillaume ^a   Forestier, Sylvie ^e   Ruszniewski, Philippe ^b   Coste, Thierry ^c   Escourrou, Jean ^d   Mignon, Michel ^a  

^a BICHAT HOSPITAL   (France)

^b BEAUJON HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

^d CHU RANGUEIL   (France)

^e Laboratoires Takeda   (France)

Author keywords

Histology; Lansoprazole; Zollinger Ellison syndrome

Indexed keywords

LANSOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MALE; TREATMENT OUTCOME; ZOLLINGER ELLISON SYNDROME; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SECRETION; STOMACH ACID; STOMACH MUCOSA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; GASTRIC MUCOSA; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; SECRETORY RATE; ZOLLINGER-ELLISON SYNDROME;

EID: 0032176248     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mignon M, Bonfils S. Diagnosis and treatment of Zollinger-Ellison syndrome. In: Piper DW, ed. Peptic Ulcer. Baillière's Clin Gastroenterol 1988;2:677-98.
2. Mignon M, Vallot T, Hervoir P, Vatier J, Bonfils S. Ranitidine vs cimetidine in the management of Zollinger-Ellison syndrome. In: Riley AJ. Salmon PR. eds. Proceedings of an International Symposium. World Congress of Gastroenterology. StockholmAmsterdam. Excerpta Medica 1982:169-77.
3. Maton PN, Gardner JD, Jensen RT. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterol Clin North Am 1989;18:847-63.
4. Lamers CBHW, Lind T, Moberg S. Jansen JBMJ, Olbe L. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in paticnts resistant to histamine H2-receptor antagonists. N Engl J Med 1984;310:758-61.
5. Delchier JC, Soulé JC, Mignon M, Goldfain D, Cortot A, Travers B, et al. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. Dig Dis Sci 1986;31:693-9.
6. Bardram L, Stadil F. Omeprazole in the Zollinger-Ellison syndrome. Scand J Gastroenterol 1986;21:374-8.
7. Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989;97:827-36.
8. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N, et al. Anutisecrelory and antiulcer activities of a novel proton pump inhibitor AG 1749 in dogs and rats. J Pharmacol Exp Ther 1989;248:806-15.
9. Lewin MJM. Effet du lansoprazole sur l'accumulation d'aminopyrine induite par l'histamine des glandes gastriques isolées de lapin: étude de la réversibilité. Takeda France Rapport Interne 1992.
10. Bruley des Varannes S, Lévy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24 hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994;8:309-14.
11. Florent C, Akrour O, Joubert-Collin M. Etude comparative des profils de pH gastrique chez le sujet sain après 7 jours de traitement par lansoprazole ou oméprazole (résumé). Gastroenterol Clin Biol 1993;17:A216.
12. Petite JP, Slama JL, Licht H, Lemerez M, Coste T, Andrieu J, et al. Comparaison du lansoprazole (30 mg) et de l'oméprazole (20 mg) dans le traitement de l'ulcère duodénal. Gastroenterol Clin Biol 1993;17:334-40.
13. Petite JP, Salducci J, Grimaud JC, Aucomte A, Hancy A, Julien H, et al. Efficacité comparée du lansoprazole et de l'oméprazole dans le traitement de l'æsophagite peptique. Med Chir Dig 1995;24:291-4.
14. Florent C, Audigicr JC, Boyer J, Camatte R, Corallo J, Delmont J, et al. Efficacy and safety of lansoprazole in the treatment of gastric ulcer: a multicentre study. Eur J Gastroenterol Hepatol 1994;6:1135-9.
15. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole (abstract). Gastroenterology 1994;106:A197.
16. Mignon M, Hochlaf S, Forestier S, Ruszniewski P, Vatier J, Joubert-Collin M. Effet dose - réponse du lansoprazole chez les malades atteints d'un syndrome de Zollinger-Ellison. Gastroenterol Clin Biol 1994;18:13-6.
17. Paul G, Ramdani A, Mignon M, Vallot T, Forestier S, Cadiot G, et al. Efficacité comparée du lansoprazole et de l'oméprazole sur le pH intragastrique mesuré sur 24 heures et sur le débit acide basal chez 9 malades atteints de syndrome de Zollinger-Ellison. Gastroenterol Clin Biol 1994;18:675-701.
18. Metz DC, Pisegna JR, Ringham GL, Feigenbaum K, Koviack PD, Maton PN, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993;38:245-56.
19. Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996;10:507-22.
20. Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Aliment Pharmacol Ther 1996;10:497-506.
21. Brunner G, Arnold R, Hennig U, Fuchs W. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1993;7 (suppl 1): 51-5.
22. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997;112:707-17.
23. Mignon M, Vallot T. Exploration de la sécrétion gastrique. In: Bernier JJ, Ed., Gastroentérologie. Paris: Flammarion Médecine Sciences, 1984:239-251.
24. Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundel G. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986;90:391-9.
25. Borch K, Renvall H, Liedberg G, Andersen BN. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986;21:357-63.
26. Lehy T, Mignon M, Cadiot G, Elouaer-Blanc L, Ruszniewski P, Lewin MJM, et al. Gastric endocrine cell behavior in ZollingerEllison patients upon long term potent antisecretory treatment. Gastroenterology 1989;96:1029-40.
27. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of non antral endocrine growths in man. Digestion 1988;41:185-200.
28. D'Adda T, Corleto V, Pilato FP, Baggi MT, Robutti F, Delle Fave G, et al. Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Correspondence with light microscopic findings. Gastroenterology 1990;99:17-26.
29. Cadiot G, Lehy T, Mignon M. Gastric endocrine cell proliferation and fundic argyrophil carcinoid tumors in patients with the Zollinger-Ellison syndrome. Acta Oncol 1993;32:135-40.
30. Cadiot G, Lehy T, Ruszniewski P, Bonfils S, Mignon M. Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment. Dig Dis Sci 1993;38:1307-17.
31. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992;33:1275-9.
32. Jensen RT. Gastrinoma as a model for prolonged hypergastrinemia in the human. In: Walsh JH, ed. Gastrin. New York. Raven, 1993:373-93.
33. Cadiot G, Laurent-Puig P, Thuille B, Lehy T, Mignon M, Olschwang S. Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome ? Gastroenterology 1993;105:579-82.
34. Cadiot G, Vissuzaine C, Potet F, Mignon M. Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci 1995;40:1275-8.